Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Evaluating the Effect of DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Patients With Newly Diagnosed High Grade B Cell Lymphoma (HGBL) With MYC and BCL2 and/or BCL6 Rearrangements

NCT03620578 is registered in ClinicalTrials.gov with Stichting Hemato-Oncologie voor Volwassenen Nederland as lead sponsor.

NCT NCT03620578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03620578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Evaluating the Effect of DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Patients With Newly Diagnosed High Grade B Cell Lymphoma (HGBL) With MYC and BCL2 and/or BCL6 Rearrangements
Lead sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 1, 2018
Completion date
October 31, 2026
Enrollment
97 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

bcl-2 translocation, high-grade b-cell lymphoma, lymphoma, b-cell, myc translocation, non hodgkin lymphoma